PEEL-224 in Solid Tumors

AddtoAny
Share:

WATCH THIS PAGE

Subscribe to be notified of changes or updates to this page.

1 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

This study enrolls patients with refractory, progressive, or relapsed solid tumors. The purpose of this study is to find out whether a drug called PEEL-224 ("the study drug") is safe and effective when given as monotherapy (a drug given by itself) and as part of a combination therapy together with other chemotherapy drugs.

Who Do I Contact?

If you are interested in participating in the study or want to learn more please contact our study team at CancerTrials [at] chop.edu or 267-425-5544.

ClinicalTrials.gov Identifier

NCT06721689

View full trial information on ClinicalTrials.gov

Eligibility & Criteria

IRB #:
24-022741
Official Title:
A Phase 1/2 Clinical Trial of the Novel Topoisomerase I Inhibitor PEEL-224 as a Single Agent and in Combination with Vincristine and Temozolomide in Children with Refractory, Progressive or Relapsed Solid Tumors
Study Phase:
Phase I
Phase II
Eligible Age Range:
1 - 30 Years
Gender:
All
Study Categories:

Visit Criteria

Participants in the research will:

  • Receive PEEL-224 infusions, either by itself or in combination with other chemotherapy drugs
  • Complete frequent clinic visits at CHOP Philadelphia campus
  • Have frequent blood tests
  • Have periodic imaging performed as part of regular cancer care to evaluate the response to treatment
  • Have research genetic tests (if not previously done clinically)
  • Submit leftover tissue samples to the study repository
  • Complete questionnaires
Leader
Jacquelyn Crane, MD

Jacquelyn Crane, MD